(Q37851009)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21386834%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

title

Taming the dragon: genomic biomarkers to individualize the treatment of cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21386834%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21386834%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Ian J Majewski

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21386834%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

author name string

Ian J Majewski

series ordinal

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21386834%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21386834%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21386834%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21386834%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

page(s)

304-312

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21386834%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nm.2311

24 January 2020

exact match

0 references

cites work

How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question

1 reference

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

MicroRNA expression profiles classify human cancers

21 January 2018

1 reference

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

21 January 2018

1 reference

Genomic signatures to guide the use of chemotherapeutics.

21 January 2018

1 reference

Do predictive signatures really predict response to cancer chemotherapy?

21 January 2018

1 reference

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

21 January 2018

1 reference

A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival

21 January 2018

1 reference

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

21 January 2018

1 reference

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

21 January 2018

1 reference

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

The mutation spectrum revealed by paired genome sequences from a lung cancer patient

21 January 2018

1 reference

A small-cell lung cancer genome with complex signatures of tobacco exposure

21 January 2018

1 reference

A comprehensive catalogue of somatic mutations from a human cancer genome

21 January 2018

1 reference

International network of cancer genome projects

21 January 2018

1 reference

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma

21 January 2018

1 reference

ARID1A mutations in endometriosis-associated ovarian carcinomas

21 January 2018

1 reference

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

21 January 2018

1 reference

Somatic mutations affect key pathways in lung adenocarcinoma

21 January 2018

1 reference

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

21 January 2018

1 reference

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

Integrative genomic profiling of human prostate cancer

21 January 2018

1 reference

Characterizing the cancer genome in lung adenocarcinoma

21 January 2018

1 reference

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

21 January 2018

1 reference

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

21 January 2018

1 reference

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

21 January 2018

1 reference

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

Genome remodelling in a basal-like breast cancer metastasis and xenograft

21 January 2018

1 reference

Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors

21 January 2018

1 reference

Development of personalized tumor biomarkers using massively parallel sequencing

21 January 2018

1 reference

Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas

21 January 2018

1 reference

Targeting the DNA repair defect of BRCA tumours

21 January 2018

1 reference

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

Reverse-phase protein lysate microarrays for cell signaling analysis

21 January 2018

1 reference

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells

21 January 2018

1 reference

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer

21 January 2018

1 reference

Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases

21 January 2018

1 reference

The grand challenge to decipher the cancer proteome.

21 January 2018

1 reference

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

21 January 2018

1 reference

Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer

21 January 2018

1 reference

NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome

21 January 2018

1 reference

The concept of synthetic lethality in the context of anticancer therapy

21 January 2018

1 reference

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

21 January 2018

1 reference

Synthetic lethal screen of an EGFR-centered network to improve targeted therapies.

21 January 2018

1 reference

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

21 January 2018

1 reference

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

21 January 2018

1 reference

Tamoxifen: a most unlikely pioneering medicine

21 January 2018

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma

21 January 2018

1 reference

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing.

21 January 2018

1 reference

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

21 January 2018

1 reference

Clinical application of the 70-gene profile: the MINDACT trial

21 January 2018

1 reference

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

21 January 2018

1 reference

Circulating tumour cells in cancer patients: challenges and perspectives

21 January 2018

1 reference

Circulating tumor cells: a window into cancer biology and metastasis

21 January 2018

1 reference

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

Circulating mutant DNA to assess tumor dynamics

21 January 2018

1 reference

Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing

21 January 2018

1 reference

BEAMing up for detection and quantification of rare sequence variants.

21 January 2018

1 reference

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer

21 January 2018

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

21 January 2018

1 reference

Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer

21 January 2018

1 reference

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

21 January 2018

1 reference

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies

21 January 2018

1 reference

CYP2D6 and tamoxifen: DNA matters in breast cancer

21 January 2018

1 reference

Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation

21 January 2018

1 reference

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

21 January 2018

1 reference

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

21 January 2018

1 reference

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

21 January 2018

1 reference

Oncogenic mutations of ALK kinase in neuroblastoma

21 January 2018

1 reference

Activating mutations in ALK provide a therapeutic target in neuroblastoma

21 January 2018

1 reference

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

21 January 2018

1 reference

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

21 January 2018

1 reference

Deriving chemosensitivity from cell lines: Forensic bioinformatics and reproducible research in high-throughput biology

21 January 2018

1 reference

Microarrays: retracing steps

21 January 2018

1 reference

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia

21 January 2018

1 reference

Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin

21 January 2018

1 reference

12 December 2020

Next-generation sequencing of plasma/serum DNA: an emerging research and molecular diagnostic tool

1 reference

12 December 2020

Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH

1 reference

12 December 2020

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors

1 reference

12 December 2020

Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients

1 reference

12 December 2020

Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors

1 reference

12 December 2020

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

12 December 2020

Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy

1 reference

12 December 2020

TAILORx: trial assigning individualized options for treatment (Rx)

1 reference

12 December 2020

Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study

1 reference

12 December 2020

Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia

1 reference

12 December 2020

Variable specimen handling affects hormone receptor test results in women with breast cancer: a large multihospital retrospective study

1 reference

12 December 2020

The importance of estrogen and progesterone receptor in primary breast cancer

1 reference

12 December 2020

Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH

1 reference

12 December 2020

Identifiers

DOI

10.1038/NM.2311

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21386834%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference